# Task 1: Cancer Genomics - Executive Summary

## üìä [View Kosmos Report on Platform](https://platform.edisonscientific.com/trajectories/561fb2fd-06c8-4a17-9ce8-9e4020f09aa0)

## Task 1: Cancer Genomics - Execution Complete ‚ùå

### Summary
Completed Task 1 of the Kosmos pilot study, testing the LITERATURE capability for synthesizing recent research on KRAS-mutant pancreatic cancer.

### Key Results:
- **Kosmos Query**: "What are the most promising targetable dependencies in KRAS-mutant pancreatic cancer identified in the last 3 years, and what mechanisms underlie resistance to current targeted therapies?"
- **Task ID**: 561fb2fd-06c8-4a17-9ce8-9e4020f09aa0
- **Kosmos Platform Link**: üîó [View Full Kosmos Report](https://platform.edisonscientific.com/trajectories/561fb2fd-06c8-4a17-9ce8-9e4020f09aa0)
- **Status**: Successfully completed
- **Duration**: ~57 minutes
- **Cost**: $200

### Evaluation Metrics:
- **Target Recall**: ‚ùå FAIL (60%) - Found 3/5 known targets (MRTX1133, SHP2, SOS1)
- **Citation Count**: ‚ùå FAIL (6) - Well below target of ‚â•20 citations
- **Citation Validity**: ‚úÖ PASS (100%) - All citations were valid (NCT trial IDs)
- **Key Paper Coverage**: ‚ùå FAIL (0%) - Did not identify any of the 3 key ground truth papers

### Key Findings from Kosmos:
1. **Identified Targets**:
   - ‚úÖ MRTX1133 (KRAS G12D inhibitor)
   - ‚úÖ SHP2 inhibitors (TNO155, RMC-4630)
   - ‚úÖ SOS1 inhibitors (BI-1701963/BI-3406)
   - ‚úÖ Additional novel target: daraxonrasib (RMC-6236) - pan-RAS inhibitor

2. **Resistance Mechanisms** (100% coverage):
   - KRAS G12D/V bypass signaling
   - MEK reactivation
   - RTK-mediated escape
   - Adaptive metabolic rewiring

3. **Clinical Trial Information**: Provided 12 NCT trial identifiers including:
   - NCT05379985 (RMC-6236 phase 1/2)
   - NCT06625320 (RMC-6236 phase 3)
   - NCT07252232 (resected PDAC study)

### What Kosmos Missed:
- **MRTX849** (adagrasib) - FDA-approved KRAS G12C inhibitor
- **RM-018** - Emerging KRAS-targeting agent
- **Key 2023 publications**:
  - MRTX1133 Nature paper (10.1038/s41586-023-06747-5)
  - SHP2 resistance Cancer Cell paper (10.1016/j.ccell.2023.01.003)
  - Pan-KRAS Science paper (10.1126/science.adg7943)

### Files Generated:
1. `/Users/ai/Documents/code/kosmos/output/task1_results/kosmos_raw_output.json` - Full Kosmos response (13,505 chars)
2. `/Users/ai/Documents/code/kosmos/output/task1_results/metrics.json` - Evaluation metrics
3. `/Users/ai/Documents/code/kosmos/output/task1_results/task1_report.md` - Complete experiment report
4. `/Users/ai/Documents/code/kosmos/input/task1_ground_truth.json` - Ground truth data
5. `/Users/ai/Documents/code/kosmos/output/task1_results/parsed_results.json` - Parsed results

### Overall Assessment: FAIL
While Kosmos provided a comprehensive synthesis of KRAS-mutant pancreatic cancer research with excellent coverage of resistance mechanisms and valid clinical trial citations, it failed to meet the minimum thresholds for target recall (60% vs 75% target), citation count (6 vs 20 target), and key paper coverage (0% vs 66% target).

### Technical Issues Identified:
- **Citation Format**: Kosmos provided NCT trial IDs rather than DOI-formatted research papers
- **Ground Truth Mismatch**: Focus on clinical trials over foundational research papers
- **Target Completeness**: Missed 2 clinically relevant KRAS inhibitors

### Recommendations:
1. **Query Refinement**: Include specific request for DOI citations and key recent publications
2. **Target Specification**: Explicitly mention specific inhibitors in queries
3. **Citation Format**: Request both clinical trial IDs and research paper DOIs

The task has been completed with all required artifacts generated and evaluated, though performance did not meet the predefined success criteria.